

# Nuclear RNA Networks, Inc.

## Our Platform is Unique

- SiRNA sequences are designed to **block pathways** instead of individual proteins or genes

## Our Molecule is Unique

- ONCO-TAG™ targets many genes within the HIPPO/Yap1 pathway
- KRAS-G12D cancers depend on HIPPO/Yap1 for therapy breakthrough

### Results summary

- KRAS-G12D pancreatic tumor inhibition:
  - *In vitro*: 95%
  - *In vivo*: 60%
- Inhibition of breast cancer cell lines